Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis

Please cite this paper as: Yin et al. (2011) Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis. Influenza and Other Respiratory Viruses 5(5), 299–305.

[1]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2012, The Cochrane database of systematic reviews.

[2]  Wen-Sen Lee,et al.  A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. , 2010, Vaccine.

[3]  P. van Damme,et al.  AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Yan Liu,et al.  A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. , 2010, The Journal of infectious diseases.

[5]  Wen-Sen Lee,et al.  Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. , 2010, Vaccine.

[6]  C. Chiu,et al.  Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. , 2010, Vaccine.

[7]  Young-Joo Ahn,et al.  Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. , 2010, Vaccine.

[8]  J. Arístegui,et al.  Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. , 2010, Vaccine.

[9]  S. Faust,et al.  Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study , 2010, BMJ : British Medical Journal.

[10]  René Ecochard,et al.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.

[11]  G. Ippolito,et al.  Evolutionary pattern of pandemic influenza (H1N1) 2009 virus in the late phases of the 2009 pandemic. , 2010, PLoS currents.

[12]  J. Devaster,et al.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.

[13]  A. Arguedas,et al.  Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. , 2010, The New England journal of medicine.

[14]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[15]  Z. Vajo,et al.  Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial , 2010, The Lancet.

[16]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[17]  M. Blatter,et al.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2010, The Lancet.

[18]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[19]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[20]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[21]  Byron C. Wallace,et al.  Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data , 2009, BMC medical research methodology.

[22]  J. Ioannidis,et al.  Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. , 2009, The Lancet. Infectious diseases.

[23]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[24]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[25]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[26]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[27]  Tom Jefferson,et al.  Vaccines for preventing influenza in the elderly. , 2010, The Cochrane database of systematic reviews.

[28]  C. Weinbaum,et al.  Early Release Morbidity and Mortality Weekly Report , 2022 .